Metraipolis › archive › dc_3156997305ec

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein — Europe PMC PMID:34871332

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34871332
DOI
10.1371/journal.ppat.1010133
License (as archived)
CC0-1.0
Archived
2026-11-01T04:00:29.926Z
SHA-256 of the archived text
4ff103ae3275b12478e2b76d6507a444b268dced295488880259ab0358faf55f
Stable URL of this page
https://metraipolis.com/documento/dc_3156997305ec

How to cite

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein — Europe PMC PMID:34871332 — Europe PMC (en), https://europepmc.org/article/MED/34871332 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_3156997305ec (Metraipolis archive dc_3156997305ec, sha256 4ff103ae3275b12478e2b76d6507a444b268dced295488880259ab0358faf55f)
BibTeX
@misc{dc3156997305ec,
  title = {Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein — Europe PMC PMID:34871332},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34871332},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_3156997305ec; sha256 4ff103ae3275b12478e2b76d6507a444b268dced295488880259ab0358faf55f},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34871332. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Combinations of monoclonal antibodies (mAbs) against different epitopes on the same antigen synergistically neutralize many viruses. However, there are limited studies assessing whether combining human mAbs against distinct regions of the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) enhances in vivo protection against malaria compared to each mAb alone or whether passive transfer of PfCSP mAbs would improve protection following vaccination against PfCSP. Here, we isolated a panel of human mAbs against the subdominant C-terminal domain of PfCSP (C-CSP) from a volunteer immunized with radiation-attenuated Pf sporozoites. These C-CSP-specific mAbs had limited binding to sporozoites in vitro that was increased by combination with neutralizing human "repeat" mAbs against the NPDP/NVDP/NANP tetrapeptides in the central repeat region of PfCSP. Nevertheless, passive transfer of repeat- and C-CSP-specific mAb combinations did not provide enhanced protection against in vivo sporozoite challenge compared to repeat mAbs alone. Furthermore, combining potent repeat-specific mAbs (CIS43, L9, and 317) that respectively target the three tetrapeptides (NPDP/NVDP/NANP) did not provide additional protection against in vivo sporozoite challenge. However, administration of either CIS43, L9, or 317 (but not C-CSP-specific mAbs) to mice that had been immunized with R21, a PfCSP-based virus-like particle vaccine that induces polyclonal antibodies against the repeat region and C-CSP, provided enhanced protection against sporozoite challenge when compared to vaccine or mAbs alone. Collectively, this study shows that while combining mAbs against the repeat and C-terminal regions of PfCSP provide no additional protection in vivo, repeat mAbs do provide increased protection when combined with vaccine-induced polyclonal antibodies. These data should inform the implementation of PfCSP human mAbs alone or following vaccination to prevent malaria infection.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2021 (prima pubblicazione 2021-12-06).
Identificativi: PMID 34871332 · PMCID PMC8675929 · DOI 10.1371/journal.ppat.1010133.
Pagina: https://europepmc.org/article/MED/34871332 — https://doi.org/10.1371/journal.ppat.1010133. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-01T03:50:47.050Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.